Related Experiment Video

Updated: Feb 19, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

19.2K

Apatinib Mesylate in the Treatment of Advanced Triple-Negative Breast Cancer

Xijia Huang1,2, Chao Chen3, Hao Zeng1,2

  • 1Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.

Oncology Research and Treatment
|February 17, 2026
PubMed
Abstract

Insights

Apatinib combined with chemotherapy and immune checkpoint inhibitors shows improved outcomes for advanced triple-negative breast cancer (TNBC). This triple therapy enhances progression-free survival compared to chemotherapy alone, offering a promising new treatment strategy.

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • Metastatic triple-negative breast cancer (TNBC) shows limited response to conventional chemotherapy.
  • Apatinib, a tyrosine kinase inhibitor (TKI), targets tumor angiogenesis and promotes apoptosis.
  • Immune checkpoint inhibitors (ICIs) offer potential for advanced TNBC but require efficacy enhancement.

Purpose of the Study:

  • To review the role of apatinib in treating TNBC.
  • To explore the mechanisms of apatinib in combination therapies for advanced TNBC.
  • To evaluate the efficacy of combining apatinib, chemotherapy, and ICIs.

Main Methods:

  • Literature review of studies on apatinib, chemotherapy, and ICIs in advanced TNBC.
  • Analysis of clinical trial data and preclinical research.
  • Examination of proposed mechanisms of action for combination therapies.

Main Results:

  • Combination of apatinib with chemotherapy and ICIs demonstrates improved progression-free survival (PFS) in advanced TNBC.
  • Apatinib can overcome chemoresistance and enhance the efficacy of PD-1 inhibitors.
  • The triple therapy exhibits synergistic effects, modifying the tumor microenvironment.

Conclusions:

  • Apatinib combined with chemotherapy and ICIs is an effective strategy for advanced TNBC.
  • This triple therapy offers a promising approach to improve outcomes in the era of immunotherapy.
  • Further clinical exploration of this combination therapy is warranted.
Keywords:
ApatinibChemotherapyImmunotherapyTriple-negative breast cancer

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.6K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
570
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
655
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K